Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon P. Nations

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Muscle & Nerve|October 4, 2002
Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravisGil I Wolfe, Richard J Barohn, Barbara M Foster, et al.
Human Mutation|March 31, 2015
Hemizygosity for SMCHD1 in Facioscapulohumeral Muscular Dystrophy Type 2: Consequences for 18p Deletion SyndromeRichard J L F Lemmers, Marlinde L van den Boogaard, Patrick J van der Vliet, et al.
Muscle & Nerve|September 8, 2018
Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trialJeffrey M Statland, Dan Moore, Yunxia Wang, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 12, 2020
Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosisHiroshi Mitsumoto, Diana C Garofalo, Regina M Santella, et al.
Neurology|January 24, 2016
Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohortJennifer Murphy, Pam Factor-Litvak, Raymond Goetz, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 26, 2014
ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristicsHiroshi Mitsumoto, Pam Factor-Litvak, Howard Andrews, et al.
The Lancet. Neurology|August 10, 2019
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trialMichael G Hanna, Umesh A Badrising, Olivier Benveniste, et al.
Neurology|February 18, 2021
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENTAnthony A Amato, Michael G Hanna, Pedro M Machado, et al.
Muscle & Nerve|December 15, 2015
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridineTed M Burns, Gordon A Smith, Jeffrey A Allen, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Muscle & Nerve|October 4, 2002
Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravisGil I Wolfe, Richard J Barohn, Barbara M Foster, et al.
Human Mutation|March 31, 2015
Hemizygosity for SMCHD1 in Facioscapulohumeral Muscular Dystrophy Type 2: Consequences for 18p Deletion SyndromeRichard J L F Lemmers, Marlinde L van den Boogaard, Patrick J van der Vliet, et al.
Muscle & Nerve|September 8, 2018
Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trialJeffrey M Statland, Dan Moore, Yunxia Wang, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 12, 2020
Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosisHiroshi Mitsumoto, Diana C Garofalo, Regina M Santella, et al.
Neurology|January 24, 2016
Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohortJennifer Murphy, Pam Factor-Litvak, Raymond Goetz, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 26, 2014
ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristicsHiroshi Mitsumoto, Pam Factor-Litvak, Howard Andrews, et al.
The Lancet. Neurology|August 10, 2019
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trialMichael G Hanna, Umesh A Badrising, Olivier Benveniste, et al.
Neurology|February 18, 2021
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENTAnthony A Amato, Michael G Hanna, Pedro M Machado, et al.
Muscle & Nerve|December 15, 2015
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridineTed M Burns, Gordon A Smith, Jeffrey A Allen, et al.
Pageof 2